Literature DB >> 18305038

Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.

Yossef Raviv1, Robert Blumenthal, S Mark Tompkins, Jennifer Humberd, Robert J Hogan, Mathias Viard.   

Abstract

The use of inactivated influenza virus for the development of vaccines with broad heterosubtypic protection requires selective inactivation techniques that eliminate viral infectivity while preserving structural integrity. Here we tested if a hydrophobic inactivation approach reported for retroviruses could be applied to the influenza virus. By this approach, the transmembrane domains of viral envelope proteins are selectively targeted by the hydrophobic photoactivatable compound 1,5-iodonaphthyl-azide (INA). This probe partitions into the lipid bilayer of the viral envelope and upon far UV irradiation reacts selectively with membrane-embedded domains of proteins and lipids while the protein domains that localize outside the bilayer remain unaffected. INA treatment of influenza virus blocked infection in a dose-dependent manner without disrupting the virion or affecting neuraminidase activity. Moreover, the virus maintained the full activity in inducing pH-dependent lipid mixing, but pH-dependent redistribution of viral envelope proteins into the target cell membrane was completely blocked. These results indicate that INA selectively blocks fusion of the virus with the target cell membrane at the pore formation and expansion step. Using a murine model of influenza virus infection, INA-inactivated influenza virus induced potent anti-influenza virus serum antibody and T-cell responses, similar to live virus immunization, and protected against heterosubtypic challenge. INA treatment of influenza A virus produced a virus that is noninfectious, intact, and fully maintains the functional activity associated with the ectodomains of its two major envelope proteins, neuraminidase and hemagglutinin. When used as a vaccine given intranasally (i.n.), INA-inactivated influenza virus induced immune responses similar to live virus infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305038      PMCID: PMC2293056          DOI: 10.1128/JVI.02233-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Self-assembly of influenza hemagglutinin: studies of ectodomain aggregation by in situ atomic force microscopy.

Authors:  R F Epand; C M Yip; L V Chernomordik; D L LeDuc; Y K Shin; R M Epand
Journal:  Biochim Biophys Acta       Date:  2001-08-06

Review 2.  Studying protein dynamics in living cells.

Authors:  J Lippincott-Schwartz; E Snapp; A Kenworthy
Journal:  Nat Rev Mol Cell Biol       Date:  2001-06       Impact factor: 94.444

Review 3.  Membrane fusion.

Authors:  Robert Blumenthal; Michael J Clague; Stewart R Durell; Richard M Epand
Journal:  Chem Rev       Date:  2003-01       Impact factor: 60.622

Review 4.  Virus-like particles as immunogens.

Authors:  Rob Noad; Polly Roy
Journal:  Trends Microbiol       Date:  2003-09       Impact factor: 17.079

5.  Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling.

Authors:  Yossef Raviv; Mathias Viard; Julian Bess; Robert Blumenthal
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

Review 6.  Control of influenza virus infection by immunity to conserved viral features.

Authors:  Suzanne L Epstein
Journal:  Expert Rev Anti Infect Ther       Date:  2003-12       Impact factor: 5.091

Review 7.  Virus-like particle and DNA-based candidate AIDS vaccines.

Authors:  Qizhi Yao; Zhigao Bu; Andrei Vzorov; Chinglai Yang; Richard W Compans
Journal:  Vaccine       Date:  2003-01-30       Impact factor: 3.641

8.  CD4 receptor localized to non-raft membrane microdomains supports HIV-1 entry. Identification of a novel raft localization marker in CD4.

Authors:  Waldemar Popik; Timothy M Alce
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

Review 9.  From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.

Authors:  John M Wood; James S Robertson
Journal:  Nat Rev Microbiol       Date:  2004-10       Impact factor: 60.633

10.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

Authors:  Suzanne L Epstein; Terrence M Tumpey; Julia A Misplon; Chia-Yun Lo; Lynn A Cooper; Kanta Subbarao; Mary Renshaw; Suryaprakash Sambhara; Jacqueline M Katz
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more
  14 in total

1.  Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.

Authors:  Kanakatte Raviprakash; Peifang Sun; Yossef Raviv; Thomas Luke; Nicholas Martin; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

2.  Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1).

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; M Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Virology       Date:  2011-07-02       Impact factor: 3.616

3.  Stability kinetics of influenza vaccine coated onto microneedles during drying and storage.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Pharm Res       Date:  2010-04-13       Impact factor: 4.200

Review 4.  Clinical vaccine development for H5N1 influenza.

Authors:  Christopher H Clegg; Joseph A Rininger; Susan L Baldwin
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

5.  Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses.

Authors:  Kathy Luinstra; Astrid Petrich; Santina Castriciano; Mona Ackerman; Sylvia Chong; Susan Carruthers; Brenna Ammons; James B Mahony; Marek Smieja
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

6.  Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1.

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; Michael Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Photochem Photobiol       Date:  2010 Sep-Oct       Impact factor: 3.421

Review 7.  Photodynamic viral inactivation: Recent advances and potential applications.

Authors:  Jace A Willis; Vsevolod Cheburkanov; Giulia Kassab; Jennifer M Soares; Kate C Blanco; Vanderlei S Bagnato; Vladislav V Yakovlev
Journal:  Appl Phys Rev       Date:  2021-06       Impact factor: 19.162

8.  Orthogonal inactivation of influenza and the creation of detergent resistant viral aggregates: towards a novel vaccine strategy.

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; Ulrich Baxa; Robert Blumenthal
Journal:  Virol J       Date:  2012-03-26       Impact factor: 4.099

9.  Inactivation of Chikungunya virus by 1,5 iodonapthyl azide.

Authors:  Anuj Sharma; Paridhi Gupta; Radha K Maheshwari
Journal:  Virol J       Date:  2012-12-04       Impact factor: 4.099

10.  Photo-activation of the hydrophobic probe iodonaphthylazide in cells alters membrane protein function leading to cell death.

Authors:  Mathias Viard; Himanshu Garg; Robert Blumenthal; Yossef Raviv
Journal:  BMC Cell Biol       Date:  2009-03-26       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.